A collection of three high-level gene and cell therapy explainers is now live on ASGCT.org. Five disease-specific topics will release through February, ultimately providing patients and patient advocates with video, text, and infographic resources to share with various stakeholders.
Milwaukee (PRWEB) January 17, 2019
The American Society of Gene & Cell Therapy (ASGCT) is proud to announce the first release of its Patient Education program, a new initiative for 2019. Designed by ASGCT committee volunteers in coordination with patient advocacy groups, the new patient-centered portal is designed to educate and inform patients, families, and the public on the status and promise of gene and cell therapies.
Gene Therapy 101, a collection of three high-level gene and cell therapy explainers, is now live on ASGCT.org. Five disease-specific topics will release through February, ultimately providing patients and patient advocates with video, text, and infographic resources to share with various stakeholders and the public. For more information, check out the ASGCT Patient Education Media Kit.
Gene Therapy Basics
Gene therapy has been studied for more than 40 years and can help stop or slow the effects of disease on the most basic level of the human body—our genes. And to understand how it works, we’ll start at the basics.
Gene therapy, cell therapy and gene editing are fields of biomedical research with a similar goal in mind: To treat disease by changing our bodies at a microscopic level. Specifically, these approaches aim to change our genetic makeup. However, each one changes our genetic material in slightly different ways. What do these approaches have in common, and what makes them different?
Developing A Treatment
Let’s learn how gene therapies go from concepts to actual treatments that can improve the lives of patients. First, the therapy spends a lot of time in preclinical studies, meaning that it is not yet ready for humans and is being researched in labs and animals to learn if it could be successful. By the time the therapy enters clinical trials for humans, it is better understood and ready for further development. Here’s more information about the process of developing a treatment.
Through February, ASGCT will release five disease-specific resources. The first disease groups were selected based on the promising statuses of their gene and cell therapy diseases:
- Spinal Muscular Atrophy—February 1
- X-Linked Myotubular Myopathy—February 12
- Leukodystrophy—February 15
- Blood Disorders—February 22
- Inherited Retinal Disorders—February 28
The American Society of Gene & Cell Therapy is the primary professional membership organization for scientists, physicians, patient advocates, and other professionals with interest in gene and cell therapy. Our members work in a wide range of settings including universities, hospitals, government agencies, foundations, biotechnology and pharmaceutical companies. ASGCT advances knowledge, awareness, and education leading to the discovery and clinical application of gene and cell therapies to alleviate human disease to benefit patients and society.